{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:57:05Z","timestamp":1790546225940,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.heliyon.2024.e32274","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T23:40:16Z","timestamp":1718062816000},"page":"e32274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["UPLC-MS\/MS determination of 71 neuropsychotropic drugs in human serum"],"prefix":"10.1016","volume":"10","author":[{"given":"Weifeng","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3259-8229","authenticated-orcid":false,"given":"Jianhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e32274_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2174\/1567201812666151029100909","article-title":"Consensus guideline based therapeutic drug monitoring (TDM) in psychiatry and neurology","volume":"13","author":"Hiemke","year":"2016","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.heliyon.2024.e32274_bib2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.heliyon.2024.e32274_bib3","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/17425255.2019.1669560","article-title":"Pharmacokinetic considerations for current state-of-the-art antidepressants","volume":"15","author":"Wyska","year":"2019","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e32274_bib4","first-page":"149s176s","article-title":"Therapeutic drug monitoring of levetiracetam in select populations","volume":"21","author":"Jarvie","year":"2018","journal-title":"J. Pharm. Pharmaceut. Sci."},{"key":"10.1016\/j.heliyon.2024.e32274_bib5","series-title":"Handbook of Clinical Applications of Therapeutic Drug Monitoring","author":"Zhang","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e32274_bib6","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in Neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2017","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.heliyon.2024.e32274_bib7","first-page":"601","article-title":"Committee on pharmacogenetic diseases, Chinese society of Pharmacology, mental health professional committee of the Chinese nursing association, expert consensus on the code of practice for therapeutic drug monitoring (2019 edition)","volume":"22","year":"2022","journal-title":"J. Neurosci. Mental Health"},{"key":"10.1016\/j.heliyon.2024.e32274_bib8","first-page":"1443","article-title":"Pharmaceutical bioanalysis committee, dalian Institute of chemical physics, Chinese academy of sciences, expert consensus on the use of chromatography for quality assurance in therapeutic drug monitoring (version 2021)","volume":"56","year":"2021","journal-title":"Chin. Pharmaceut. J."},{"key":"10.1016\/j.heliyon.2024.e32274_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25174026","article-title":"Review of chromatographic methods coupled with modern detection Techniques applied in the therapeutic drugs monitoring (TDM)","volume":"25","author":"Tuzimski","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.heliyon.2024.e32274_bib10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/17425255.2020.1724956","article-title":"Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects","volume":"16","author":"Johannessen Landmark","year":"2020","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e32274_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinbiochem.2020.03.004","article-title":"After another decade: LC\u2013MS\/MS became routine in clinical diagnostics","volume":"82","author":"Seger","year":"2020","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.heliyon.2024.e32274_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5090","article-title":"A UPLC\u2013MS\/MS method for simultaneous determination of nine antiepileptic drugs in human plasma and its application in TDM","volume":"35","author":"Qi","year":"2021","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.heliyon.2024.e32274_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/FTD.0000000000000115","article-title":"High-throughput method for the quantification of lacosamide in serum using ultrafast SPE-MS\/MS","volume":"37","author":"Korman","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.heliyon.2024.e32274_bib14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/chromsci\/bmy040","article-title":"LC\u2013MS-MS determination of oxcarbazepine and an active metabolite in human plasma for clinical application","volume":"56","author":"Mano","year":"2018","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.heliyon.2024.e32274_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.864","article-title":"Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders","volume":"9","author":"Sagah\u00f3n\u2010Az\u00faa","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.heliyon.2024.e32274_bib16","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/jcm9040915","article-title":"Deproteinization as a rapid method of saliva purification for the determination of carbamazepine and carbamazepine-10,11 epoxide","volume":"9","author":"Dziurkowska","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.heliyon.2024.e32274_bib17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.12740\/PP\/85788","article-title":"Sertraline \u2013 isolation methods and quantitation in biological material","volume":"52","author":"Dziurkowska","year":"2018","journal-title":"Psychiatr. Pol."},{"key":"10.1016\/j.heliyon.2024.e32274_bib18","first-page":"28","article-title":"Determination of drugs in plasma samples by high-performance liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of schizophrenic patients","volume":"40","author":"Domingues","year":"2016","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e32274_bib19","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.3390\/molecules24203636","article-title":"Determination of antidepressants and antipsychotics in dried blood spots (DBSs) collected from post-mortem samples and evaluation of the stability over a three-month period","volume":"24","author":"Moretti","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.heliyon.2024.e32274_bib20","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/dta.2784","article-title":"Hair analysis of antidepressants and antipsychotics\u2014overview of quantitative data","volume":"12","author":"Methling","year":"2020","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.heliyon.2024.e32274_bib21","doi-asserted-by":"crossref","DOI":"10.2174\/1389201020666190830150549","article-title":"A UPLC-MS\/MS assay for simultaneous determination of two antipsychotics and two antidepressants in human plasma and its application in clinic","volume":"21","author":"Li","year":"2020","journal-title":"Curr. Pharmaceut. Biotechnol."},{"key":"10.1016\/j.heliyon.2024.e32274_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1373\/clinchem.2015.238626","article-title":"Clsi C62-A: a new standard for clinical mass spectrometry","volume":"62","author":"Lynch","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.heliyon.2024.e32274_bib23","series-title":"Pharmacopoeia of the People's Republic of China (2 0 2 0 Edition)","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e32274_bib24","article-title":"Analysis of the development status of neuropsychiatric therapeutic drug monitoring in terms of the external","volume":"1","author":"Zhang","year":"2019","journal-title":"Quality Evaluation, China Pharmacy"},{"key":"10.1016\/j.heliyon.2024.e32274_bib25","article-title":"Investigation of psychiatric therapeutic drug monitoring in South China and its surrounding region","volume":"6","author":"yang Lu","year":"2020","journal-title":"The Chin. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e32274_bib26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jchromb.2006.05.031","article-title":"Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach","volume":"843","author":"Kirchherr","year":"2006","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.heliyon.2024.e32274_bib27","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s00216-011-4959-6","article-title":"Full validation and application of an ultra high performance liquid chromatographic-tandem mass spectrometric procedure for target screening and quantification of 34 antidepressants in human blood plasma as part of a comprehensive multi-analyte approach","volume":"400","author":"Remane","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.heliyon.2024.e32274_bib28","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1007\/s00216-014-8019-x","article-title":"Quantification of 33 antidepressants by LC-MS\/MS\u2014comparative validation in whole blood, plasma, and serum","volume":"406","author":"Montenarh","year":"2014","journal-title":"Analytical and Bioanalytical Chemistry\/Anal. Bioanal. Chem."},{"key":"10.1016\/j.heliyon.2024.e32274_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/5807218","article-title":"Determination of chlorpromazine, haloperidol, levomepromazine, olanzapine, risperidone, and sulpiride in human plasma by liquid chromatography\/tandem mass spectrometry (LC-MS\/MS)","volume":"2018","author":"Khelfi","year":"2018","journal-title":"Int. J. Anal. Chem."},{"key":"10.1016\/j.heliyon.2024.e32274_bib30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/FTD.0000000000000197","article-title":"Simple and accurate quantitative analysis of 16 antipsychotics and antidepressants in human plasma by ultrafast high-performance liquid chromatography\/tandem mass spectrometry","volume":"37","author":"Wang","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.heliyon.2024.e32274_bib31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/DDDT.S290963","article-title":"Ultra-Performance liquid chromatography-tandem mass spectrometry for simultaneous determination of antipsychotic drugs in human plasma and its application in therapeutic drug monitoring","volume":"15","author":"Qi","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.heliyon.2024.e32274_bib32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/FTD.0000000000000516","volume":"40","author":"Palte","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.heliyon.2024.e32274_bib33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/01612840.2019.1652870","article-title":"Improving access to laboratory monitoring in individuals living with serious mental illness","volume":"40","author":"Hamm","year":"2019","journal-title":"Issues Ment. Health Nurs."},{"key":"10.1016\/j.heliyon.2024.e32274_bib34","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s12272-013-0225-0","article-title":"Screening of multiple drugs of abuse and metabolites in urine using LC\/MS\/MS with polarity switching electrospray ionization","volume":"37","author":"Shin","year":"2013","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.heliyon.2024.e32274_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.787043","article-title":"Therapeutic reference ranges for psychotropic drugs: a protocol for systematic reviews","volume":"12","author":"Hart","year":"2021","journal-title":"Front. Psychiatr."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024083051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024083051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:10:25Z","timestamp":1790543425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024083051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2405844024083051"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32274","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UPLC-MS\/MS determination of 71 neuropsychotropic drugs in human serum","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32274","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e32274"}}